Table III.
Network meta-analysis of PASI 75 response rate between drugs for treating psoriasis.
| CSA | Etanercept | Infliximab | Ustekinumab | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs | Adalimumab | Briakinumab | 2.5 mg | 5 mg | 100 mg QW | 25 mg BIW | 25 mg QW | 50 mg BIW | 50 mg QW | 3 mg | 5 mg | MTX | Placebo | 45 mg | 90 mg |
| Adalimumab | – | 2.25 | 0.31 | 1.50 | 0.37 | 0.43 | 0.10 | 0.55 | 0.25 | 1.39 | 3.04 | 0.39 | 0.03 | 0.91 | 1.04 |
| (0.49,7.32) | (0.08,1.34) | (0.34,8.64) | (0.06,1.53) | (0.11,1.59) | (0.02,0.45) | (0.11,1.67) | (0.04,0.94) | (0.37,4.75) | (0.99,8.77) | (0.16,1.02) | (0.02,0.06) | (0.22,2.54) | (0.25,2.91) | ||
| Briakinumab | 0.44 | – | 0.14 | 0.67 | 0.16 | 0.20 | 0.04 | 0.23 | 0.11 | 0.62 | 1.37 | 0.18 | 0.01 | 0.40 | 0.46 |
| (0.14,2.03) | (0.03,1.01) | (0.12,6.22) | (0.04,0.61) | (0.07,0.69) | (0.01,0.19) | (0.05,1.03) | (0.03,0.37) | (0.18,2.46) | (0.44,4.88) | (0.05,0.70) | (0.01,0.03) | (0.15,1.02) | (0.18,1.17) | ||
| CSA 2.5 mg | 3.22 | 7.11 | – | 4.98 | 1.16 | 1.43 | 0.34 | 1.74 | 0.78 | 4.42 | 9.89 | 1.29 | 0.09 | 2.88 | 3.32 |
| (0.74,12.82) | (0.99,36.73) | (1.75,13.54) | (0.13,7.39) | (0.24,7.30) | (0.04,2.07) | (0.23,8.30) | (0.10,4.39) | (0.85,20.65) | (2.18,39.43) | (0.37,3.97) | (0.01,0.35) | (0.46,12.78) | (0.51,14.83) | ||
| CSA 5 mg | 0.67 | 1.49 | 0.20 | – | 0.24 | 0.29 | 0.07 | 0.36 | 0.16 | 0.91 | 2.06 | 0.44 | 0.02 | 0.60 | 0.69 |
| (0.12,2.95) | (0.16,8.29) | (0.07,0.57) | (0.02,1.67) | (0.04,1.67) | (0.01,0.47) | (0.03,1.95) | (0.01,1.02) | (0.12,4.84) | (0.30,9.18) | (0.14,1.57) | (0.00,0.08) | (0.07,2.96) | (0.08,3.38) | ||
| Etanercept | 2.73 | 6.15 | 0.86 | 4.15 | – | 1.23 | 0.28 | 1.46 | 0.66 | 3.85 | 8.51 | 1.11 | 0.07 | 2.48 | 2.85 |
| 100 mg QW | (0.65,17.41) | (1.63,23.99) | (0.14,7.79) | (0.60,51.05) | (0.35,5.34) | (0.08,1.07) | (0.62,3.62) | (0.22,2.09) | (0.86,19.38) | (2.13,40.28) | (0.26,5.97) | (0.02,0.24) | (0.80,7.72) | (0.91,8.85) | |
| Etanercept | 2.32 | 5.07 | 0.70 | 3.40 | 0.82 | – | 0.28 | 1.43 | 0.55 | 3.19 | 7.09 | 0.90 | 0.06 | 2.02 | 2.32 |
| 25 mg BIW | (0.63,8.84) | (1.44,14.66) | (0.14,4.22) | (0.60,27.08) | (0.19,2.89) | (0.06,1.16) | (0.39,4.95) | (0.15,1.65) | (0.77,11.49) | (1.92,22.79) | (0.24,3.19) | (0.02,0.13) | (0.72,4.84) | (0.81,5.63) | |
| Etanercept | 9.73 | 22.27 | 2.97 | 14.40 | 3.55 | 3.60 | – | 5.25 | 2.37 | 13.91 | 29.78 | 3.86 | 0.26 | 8.81 | 10.19 |
| 25 mg QW | (2.22,58.96) | (5.23,85.70) | (0.48,27.13) | (2.13,179.59) | (0.94,12.49) | (0.86,16.14) | (1.99,13.30) | (0.73,7.27) | (2.92,65.68) | (7.31,139.88) | (0.91,20.80) | (0.05,1.37) | (2.69,28.14) | (3.01,31.84) | |
| Etanercept | 1.83 | 4.29 | 0.58 | 2.75 | 0.69 | 0.70 | 0.19 | – | 0.45 | 2.65 | 5.70 | 0.74 | 0.05 | 1.68 | 1.85 |
| 50 mg BIW | (0.60,9.27) | (0.97,18.85) | (0.12,4.32) | (0.51,30.05) | (0.28,1.62) | (0.20,2.55) | (0.08,0.50) | (0.23,0.89) | (0.76,10.26) | (1.94,21.09) | (0.24,3.10) | (0.01,0.21) | (0.81,3.59) | (0.48,7.46) | |
| Etanercept | 4.05 | 9.31 | 1.28 | 6.17 | 1.51 | 1.81 | 0.42 | 2.21 | – | 5.75 | 12.64 | 1.65 | 0.11 | 3.75 | 4.28 |
| 50 mg QW | (1.07,23.01) | (2.69,31.37) | (0.23,10.48) | (0.98,71.10) | (0.48,4.51) | (0.61,6.84) | (0.14,1.36) | (1.12,4.33) | (1.43,27.06) | (3.64,54.57) | (0.44,7.93) | (0.04,0.30) | (1.36,9.87) | (1.56,11.25) | |
| Infliximab | 0.72 | 1.61 | 0.23 | 1.10 | 0.26 | 0.31 | 0.07 | 0.38 | 0.17 | – | 2.18 | 0.29 | 0.02 | 0.65 | 0.74 |
| 3 mg | (0.21,2.67) | (0.41,5.67) | (0.05,1.17) | (0.21,8.04) | (0.05,1.16) | (0.09,1.30) | (0.02,0.34) | (0.10,1.31) | (0.04,0.70) | (1.10,4.75) | (0.10,0.87) | (0.01,0.05) | (0.19,1.97) | (0.21,2.29) | |
| Infliximab | 0.33 | 0.73 | 0.10 | 0.49 | 0.12 | 0.14 | 0.03 | 0.18 | 0.08 | 0.46 | – | 0.13 | 0.01 | 0.29 | 0.34 |
| 5 mg | (0.11,1.01) | (0.20,2.28) | (0.03,0.46) | (0.11,3.34) | (0.02,0.47) | (0.04,0.52) | (0.01,0.14) | (0.05,0.51) | (0.02,0.27) | (0.21,0.91) | (0.06,0.31) | (0.00,0.02) | (0.09,0.78) | (0.11,0.90) | |
| MTX | 2.55 | 5.57 | 0.78 | 2.25 | 0.90 | 1.11 | 0.26 | 1.35 | 0.61 | 3.49 | 7.69 | – | 0.05 | 2.26 | 2.59 |
| (0.99,6.18) | (1.42,18.42) | (0.25,2.68) | (0.64,6.94) | (0.17,3.89) | (0.31,4.20) | (0.05,1.10) | (0.32,4.20) | (0.13,2.26) | (1.15,9.75) | (3.28,17.36) | (0.00,0.15) | (0.63,6.30) | (0.72,7.30) | ||
| Placebo | 30.93 | 84.29 | 11.71 | 55.90 | 13.57 | 16.61 | 3.83 | 20.24 | 9.10 | 53.49 | 117.81 | 19.04 | – | 33.57 | 38.81 |
| (16.26,58.97) | (37.74,187.34) | (2.86,69.09) | (12.23,452.23) | (4.22,41.45) | (7.77,43.27) | (0.73,18.81) | (4.73,75.32) | (3.34,24.47) | (19.24,158.08) | (54.46,286.70) | (6.83,242.20) | (20.28,55.73) | (22.22,64.79) | ||
| Ustekinumab | 1.09 | 2.48 | 0.35 | 1.66 | 0.40 | 0.49 | 0.11 | 0.60 | 0.27 | 1.54 | 3.43 | 0.44 | 0.03 | – | 1.19 |
| 45 mg | (0.39,4.55) | (0.98,6.47) | (0.08,2.18) | (0.34,14.71) | (0.13,1.26) | (0.21,1.38) | (0.04,0.37) | (0.28,1.23) | (0.10,0.74) | (0.51,5.35) | (1.28,10.57) | (0.16,1.58) | (0.02,0.05) | (0.34,4.29) | |
| Ustekinumab | 0.96 | 2.17 | 0.30 | 1.44 | 0.35 | 0.43 | 0.10 | 0.54 | 0.23 | 1.36 | 2.97 | 0.39 | 0.03 | 0.84 | – |
| 90 mg | (0.34,3.97) | (0.85,5.68) | (0.07,1.95) | (0.30,13.07) | (0.11,1.10) | (0.18,1.23) | (0.03,0.33) | (0.13,2.07) | (0.09,0.64) | (0.44,4.82) | (1.11,9.46) | (0.14,1.40) | (0.02,0.05) | (0.23,2.94) | |
PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.